Rapport Therapeutics Inc
Research Rapport Therapeutics Inc (RAPP) on Bullrun: market cap USD 2.45B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRAPP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.45B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 56.62M
- Free cash flow-USD 41.53M
Valuation Snapshot
latest market cap is USD 2.45B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 111.48M | -USD 88.09M | n/a | -2.86 | USD 52.65M | USD 11.48M | USD 484.65M |
| FY2024 | USD 0 | -USD 78.31M | -USD 67.23M | n/a | -3.78 | USD 56.81M | USD 1.48M | USD 305.43M |
| FY2023 | n/a | -USD 34.79M | -USD 28.82M | n/a | -23.1 | USD 70.17M | USD 2.15M | -USD 25.63M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.45B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.45B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 648.93M | n/a | n/a | n/a |
About Rapport Therapeutics Inc
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Rapport Therapeutics Inc's market cap?
Rapport Therapeutics Inc's market capitalization is USD 2.45B.
What does Rapport Therapeutics Inc do?
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.